News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Evommune (NYSE:EVMN) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.

Evommune Announces $125 Million Private Placement

Evommune (NYSE:EVMN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.

Evommune (NYSE:EVMN) had its price target raised by analysts at HC Wainwright from $35.00 to $65.00. They now have a "buy" rating on the stock.

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Form 4 Evommune, Inc. For: Feb 17 Filed by: LSP 7 Cooperative UA

Form SCHEDULE 13D/A Evommune, Inc. Filed by: LSP 7 Cooperative UA

Form 4 Evommune, Inc. For: Feb 17 Filed by: Verduyn-van Weegen Felice Isabel

Form SCHEDULE 13D/A Evommune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Form 4 Evommune, Inc. For: Feb 17 Filed by: Shah Rajeev M.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}